My group is interested in epigenetic regulation of somatic mutagenesis in normal and malignant B cells. We aim to understand how alterations in the nuclear envelope influence B cell chromatin conformation, and what the epigenetic consequences of these alterations are.
My group works on developing novel approaches to improve efficacy and safety of allogeneic stem cell transplantation and adoptive immunotherapy as treatments for blood cancers. We focus on T-cell alloreactivity in the context of stem cell transplantation and immunotherapy.
Our research aims to understand the epigenetic regulation of transposable elements and how their dysregulation contributes to the generation and development of cancer. In particular, we investigate their roles as gene regulators and triggers of anti-tumour immunity in blood cancers.
My group aims to discover the epigenetic changes taking place during cancer initiation and develop potential drugs that can prevent these changes which may be abnormal but reversible, before many damaging mutations occur.
My research interests focus on mechanisms of disease initiation and maintenance and the identification and validation of novel therapeutic targets in myeloid leukaemias.
Our goal is to identify mechanisms that support haematopoietic stem cell function and understand how the leukaemic stem cells “play” with these mechanisms to thrive.
My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
The central aim of our laboratory is to understand the biology of leukaemic stem cells and identify therapeutic targets to specifically eradicate them, thus discovering novel and efficient leukaemia therapies. We also focus on understanding haematopoietic stem cell biology with the hope to harness this knowledge for expanding them for therapeutic purposes.
My studies concentrate on the immunogenetics of human B cell malignancies, such as chronic lymphocytic leukaemia, follicular lymphoma and the role for B cell receptor in the pathogenesis of B cell lymphoma and leukaemia.
I am the Module Lead for 3 undergraduate Biomedical Science Modules. I am also the Cancer Theme Lead for MBBS with direct responsibility for Year 2 Cancer Week. In addition, I supervise MSc project dissertations.
The overarching goal of our laboratory is to understand the biology of normal haematopoietic and leukaemic stem cells in order to selectively kill cancer stem cells for better leukaemia treatment.
My research focuses on understanding the genetic and molecular mechanisms that underlie the initiation and progression of B-cell non-Hodgkin’s lymphomas in order to define clinically-relevant biomarkers.
My major research interest is understanding the metabolism of chronic lymphocytic leukaemia and lymphoma with the aim that this will underpin the development of the next generation of anti-metabolic drugs for these diseases.
My main research interests are in haematopoietic stem cells (HSCs) and leukemic initiating cells. I seek to understand how intrinsic and extrinsic signals are integrated by normal and malignant stem cells.
We are interested in understanding the cellular and molecular mechanisms responsible for relapses in acute lymphoblastic leukaemia and progressing these insights into translational diagnostics and clinical trials.